OTCM
NIRVF
Market cap275kUSD
Jan 30, Last price
0.01USD
Name
Nirvana Life Sciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
0k
P
CFO
-333k
L-32.02%
Profile
Nirvana Life Sciences Inc. engages in the scientific research and development of therapeutic products derived from psychedelics. It also focuses on developing methodologies for extraction and purification of psychoactive compounds; and the improvement of propagation techniques for growing such biomass on a large scale. The company was incorporated in 2020 and is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑04 | 2022‑04 | 2020‑10 | 2019‑10 | 2018‑10 | |
| Income | |||||
Revenues | |||||
Cost of revenue | |||||
Unusual Expense (Income) | |||||
NOPBT | |||||
NOPBT Margin | |||||
Operating Taxes | |||||
Tax Rate | |||||
NOPAT | |||||
Net income | |||||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 150 | ||||
BB yield | |||||
| Debt | |||||
Debt current | 58 | ||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | 46 | ||||
| Cash flow | |||||
Cash from operating activities | (333) | ||||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | 310 | ||||
FCF | 720 | ||||
| Balance | |||||
Cash | 12 | ||||
Long term investments | |||||
Excess cash | 12 | ||||
Stockholders' equity | (1,367) | ||||
Invested Capital | 485 | ||||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 34 | ||||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | 92 | ||||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||